Evidence map›Paper›PMID 41214778›Full record

ArticleJournal of neuroinflammation2025

Profilin 1 controls a microglial cytoskeleton checkpoint to prevent senescence and premature synaptic decline.

Camila Cabral Portugal, Tiago Oliveira Almeida, Joana Tedim-Moreira, Cátia Silva, Teresa Canedo, João Galvão, Ana Magalhães, Teresa Summavielle, Xianshu Bai, Frank Kirchhoff and 8 more

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Camila Cabral Portugali3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Tiago Oliveira Almeidai3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Joana Tedim-Moreirai3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Cátia Silvai3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Teresa Canedoi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
João Galvãoi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Ana Magalhãesi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Teresa Summaviellei3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
Xianshu BaiDepartment of Molecular Physiology, Center for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, 66421, Homburg, Germany.
Frank KirchhoffDepartment of Molecular Physiology, Center for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, 66421, Homburg, Germany.
Boris RubinsteinStowers Institute for Medical Research, Kansas City, MO, USA.
Irina MoreiraCNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Jéssica CostaCNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Joana GuedesCNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Inês Mendes Pintoi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal.
João PeçaCNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Renato Socodatoi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal. renato.socodato@ibmc.up.pt.
João Bettencourt Relvasi3S - Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal. jrelvas@ibmc.up.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Profilin 1 (Pfn1) expression decreases significantly in aged human microglia, suggesting that loss of cytoskeletal integrity may trigger microglial senescence and increased synaptic vulnerability. To test this hypothesis, we used an inducible, microglia-specific Pfn1 knockout in adult mice, a strategy designed to isolate the direct effects of acute Pfn1 loss at the cellular and circuit levels, avoiding confounding factors from development or chronic aging. Using a multi-omics approach combined with intravital two-photon imaging, we found that Pfn1 ablation disrupts actin–microtubule coupling, leading to a collapse of microglial morphodynamics and a complete failure to respond to focal brain injury. This cytoskeletal disruption triggers a cell-autonomous, senescence-associated secretory phenotype (SASP), driven by the ERK/NF-κB signaling axis. SASP factors secreted by Pfn1-deficient microglia reprogram the synaptic environment, resulting in significant deficits in mitochondrial energy production and a selective reduction in the frequency of GABAergic inhibitory postsynaptic currents in the prefrontal cortex. These circuit-level disturbances lead to behaviors characterized by altered anxiety and risk assessment. Our findings identify Pfn1 as a critical checkpoint against microglial senescence and show that its loss is sufficient to drive circuit-specific synaptic decline, highlighting the Pfn1-cytoskeleton axis as a potential therapeutic target to enhance brain resilience.

Indexed as

Cellular SenescenceCytoskeletonMicrogliaProfilinsSynapsesAnimalsMiceMice, KnockoutPfn1 protein, mouseProfilins

Identifiers

PMID41214778
PMCPMC12604266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.